Why do you get tdap vaccine while pregnant

Overview

The Tdap vaccine, which protects against tetanus, diphtheria, and pertussis (whooping cough), has been recommended for pregnant individuals since 2012 when the Advisory Committee on Immunization Practices (ACIP) first issued this guidance. This recommendation was strengthened in 2013 to specify administration during each pregnancy, regardless of previous Tdap vaccination history. The rationale stems from the vulnerability of newborns to pertussis, which causes approximately 160,700 deaths globally each year according to WHO estimates. In the United States alone, there were over 15,000 reported pertussis cases in 2023, with infants under 6 months experiencing the highest rates of hospitalization and death. Historically, before maternal vaccination recommendations, over 90% of pertussis deaths occurred in infants too young to be fully vaccinated. The current approach represents a shift from the previous strategy of "cocooning" (vaccinating family members around the infant) to direct maternal immunization, which has proven more effective at protecting newborns.

How It Works

The Tdap vaccine works by stimulating the pregnant person's immune system to produce antibodies against tetanus, diphtheria, and pertussis bacteria. When administered during the third trimester (optimally between 27-36 weeks), these protective antibodies cross the placenta through active transport mechanisms, providing the developing fetus with passive immunity. This process, known as transplacental antibody transfer, peaks during the final weeks of pregnancy, with IgG antibodies efficiently crossing the placental barrier. The vaccine contains inactivated toxins (toxoids) from tetanus and diphtheria bacteria, along with purified components of Bordetella pertussis, the bacterium that causes whooping cough. These components trigger B-cells to produce specific antibodies that neutralize the toxins and prevent bacterial adhesion. The transferred antibodies remain in the newborn's bloodstream for approximately the first two months of life, bridging the immunity gap until the infant can receive their first DTaP vaccine at 2 months of age. This mechanism has been shown to provide more consistent protection than the previous "cocooning" strategy, which relied on vaccinating family members.

Why It Matters

Maternal Tdap vaccination matters because it directly addresses the most vulnerable period in infant health - the first months of life when babies cannot yet be vaccinated themselves. Pertussis is particularly dangerous for infants, with approximately 50% of those under 1 year who contract the disease requiring hospitalization, and about 1 in 100 hospitalized infants dying from complications. The real-world impact is substantial: studies show maternal Tdap vaccination prevents an estimated 70% of pertussis cases in infants under 2 months and reduces hospitalization rates by similar percentages. This protection extends beyond individual families to community immunity, helping control pertussis outbreaks. The practice has become standard obstetric care in many countries, with vaccination rates among pregnant people exceeding 50% in the U.S. as of 2023. Beyond immediate infant protection, this strategy also provides tetanus protection for both mother and baby during delivery, preventing maternal and neonatal tetanus, which still causes approximately 34,000 newborn deaths globally each year according to WHO data.